WorldPing logo WorldPing← All news

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: TechCrunch

What happened

The round valued the AI biotech at $2 billion.

It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Key facts

  • The round valued the AI biotech at $2 billion.
  • It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
  • Reported by TechCrunch and published Wed, 23 Sep 2026 19:31:28 UTC.

Why it matters

Platform, chip and AI decisions set the terms other companies have to build on, so a single announcement here tends to ripple through products, supply chains and regulation.

What to watch next

  • Availability, pricing and rollout regions
  • Independent testing or verification of the claims made
  • Responses from regulators and competing platforms

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

  2. Meta brings FDA-cleared hearing enhancement to its smart glasses

Sources

The original report was published by TechCrunch. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at TechCrunch

Follow the story

Living hubs that keep updating as this story develops.

Related WorldPing coverage